Carebastine, a histamine H1 antagonist, is under development by Almirall Prodesfarma for the potential treatment of allergic rhinitis, asthma and conjunctivitis. A nasal formulation was submitted for registration in Spain in June 1999 [343595]. It is also in phase III trials for conjunctivitis and phase I trials for asthma [343144,343243]. In a multicentered, multinational, double-blind, placebo-controlled study in patients with symptomatic SAR, patients were assigned a nasal spray formulation of carebastine (2.5 mg/ml) or placebo. Severity scores decreased significantly with carebastine compared to placebo. This findings suggest that carebastine nasal spray has the potential to be of value in the treatment of SAR [282185]. In a multicenter, multinational, double-blind, randomized, placebo-controlled study, patients with seasonal allergic conjunctivitis (SAC) were assigned an eye drop formulation of carebastine (25 mg/ml) or placebo. Carebastine was significantly better than placebo at relieving the effects of SAC, as early as 15 min after administration and the effect lasted for 14 days. Carebastine was well-tolerated and there were no difference in adverse events between the two groups [282897].